D-0719-2022 Class II Terminated
FDA drug recall D-0719-2022 was initiated by Olympia Compounding Pharmacy Dba Olympia Pharmacy on Mar 8, 2022 and is designated Class II. Reason for recall: Product found to be Sub Potent or Exceeded reconstitution time The recall status is terminated (terminated Oct 4, 2023). Affected quantity: 2634 vials.
Recall Details
- Product Type
- Drugs
- Report Date
- Mar 30, 2022
- Initiation Date
- Mar 8, 2022
- Termination Date
- Oct 4, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2634 vials
Product Description
NAD+ Nicotinamide Adenine Dinucleotide, Lyophilized powder for reconstitution, Multi-Dose 500 mg per vial, Each ML contains: 0.288% Sodium Phosphate Monobasic USP, 0.42% Sodium Phosphate Dibasic USP, 5% Mannitol USP, Sterile Water for Injection USP, Rx Only, Olympia Pharmaceuticals 6700 Conroy Rd., Ste. 155, Orlando, FL 32835 NDC: 73198-0083-00
Reason for Recall
Product found to be Sub Potent or Exceeded reconstitution time
Distribution Pattern
Nationwide in the USA including Puerto Rico.
Code Information
Lot: D24005 Exp. 4/5/22; C41008 Exp. 3/8/22
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0719-2022
- openFDA file date
- Oct 23, 2026
- Loaded by RegDataLab
- Oct 25, 2026